Tempus AI, Inc. - Class A Common Stock (TEM)

AI is reshaping healthcare by improving outcomes and easing burnout. See how three companies are leading this transformation

These two tech stocks could deliver big returns for investors willing to hold for the long term.

Tempus AI (NASDAQ: TEM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

When a well-known growth investor decides to trim her position in a stock, investors sit up and take note.

On Wednesday Sept. 24, 2025, Cathie Wood-led Ark Invest purchased nearly $11 million worth of Alibaba stock while selling shares of AMD and Tempus AI.

Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They also made other key trades.

HIMS, DLO, and TEM combine high short interest with bullish chart setups, creating strong breakout potential as market momentum stays hot.

The company is focusing on RNA sequencing as a means of assisting with drug development.

Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),

On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. (NASDAQ:AMD) and Bullish Inc. (NYSE:BLSH), while selling shares o

Tempus AI stock is trading marginally lower on Monday. Recent bullish sentiment follows last Thursday's announcement that Tempus AI received 510(k) clearance from the FDA.

Cathie Wood-led Ark Invest sold shares of Tempus AI, bought Bullish, Amazon, and Figma. The moves align with recent achievements and advancements of the companies.

The AI heathcare tech specialist is about to put another product on the market.

Tempus AI's Tempus Pixel received FDA clearance for cardiac imaging updates, adding T1/T2 maps to enhance MR image analysis and diagnosis precision.

Shares jumped into a profit-taking zone Thursday after the FDA cleared its updated cardiac-imaging platform.

Artificial intelligence is the hottest investing trend of 2025.

Revenue growth is soaring for TempusAI, and that has investors excited.

On Tuesday, Cathie Wood-led Ark Invest sold shares of Tempus AI Inc (NASDAQ: TEM) through ARK Genomic Revolution ETF (ARKG) and ARK Innovation ETF (ARKK) totaling $2.1 million. This follows Tempus AI's recent acquisition and mixed analyst ratings. Other key trades include purchases of Prime Medicine Inc (PRME) and Twist Bioscience Corp (TWST).

Tempus AI (TEM) excels with a perfect technical rating, accelerating revenue growth of 89.57%, and strong earnings momentum, fitting the high-growth Minervini Trend Template.

Bearish investors are hammering these three stocks with short selling. However, all three have promising developments on their side that bears may be missing.